(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 4 November 2004 (04.11.2004)

(10) International Publication Number WO 2004/093781 A2

(51) International Patent Classification7:

A61K

English

(21) International Application Number:

PCT/SE2004/000590

(22) International Filing Date: 15 April 2004 (15.04.2004)

(25) Filing Language:

English

(30) Priority Data:

(26) Publication Language:

0301202-8 24 April 2003 (24.04.2003) 60/468,054 6 May 2003 (06.05.2003)

(71) Applicant (for all designated States except US): AXELAR AB [SE/SE]; c/o Karolinska Innovations AB, Fogdevreten 2B, S-171 77, Stockholm (SE).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): AXELSON, Magnus [SE/SE]; Riddersviksvägen 170, S-165 72 Hässelby (SE). LARSSON, Olle [SE/SE]; Svarsgränd 9, S-187 42 Täby (SE).
- (74) Agents: LARFELDT Helene et al.; Bergenstråhle & Lindvall AB, Box 17704, S-118 93 Stockholm (US).


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: NEW USE AND NEW COMPOUNDS



(57) Abstract: The invention refers to new compounds as well as to the use thereof and of known compounds as specific inhibitors of the insulin-like growth factor-1 receptor (IGF-1R). Said compounds can be used for treatment of IGF-1/IGF-1R dependent diseases, such as cancer, psoriasis, arteriosclerosis, certain endocrine and metabolic disorders etc.

WO 2004/093781 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.